Abstract 2260: CD151 immunoreactivity at diagnosis predicts early biochemical failure and metastasis in prostate cancer
Notice bibliographique
Résumé
Abstract Background: One in seven men will be diagnosed with prostate cancer (PCa) during their lifetime and nearly 25% of those will die as a result of metastatic disease. Current diagnostic methods for PCa fail to predict which patients harbor occult metastases and although Epstein's criteria are useful in establishing relative risk, a significant number of patients diagnosed with “low risk” PCa develop metastasis. Clearly, there is a need for more accurate prognostic tools to determine which patients are at higher risk of suffering metastasis. We have previously demonstrated that tetraspanin CD151 plays a role in tumor cell motility and metastasis that is dependent upon an extracellular epitope recognized by the monoclonal antibody 1A5 (mAb 1A5). We surmised that this antibody might specifically recognize a pool of CD151 that is relevant for clinical metastasis. In this study, we evaluate the role of CD151 as detected by mAb 1A5 as a molecular prognostic factor for PCa disease progression and metastasis. Methods: Specimens from 99 patients who underwent radical prostatectomy (RP) between 1994-1998 with pathological pT2 and pT3 were assessed by immunohistochemistry using mAb 1A5 with a mean follow up of 12.1 years ± 1.6 SD. After deparaffinization, immunohistochemical analysis was carried out and protein expression was categorized as negative (score=0); or positive in weak (1), moderate (2) and strong (3). CD151 analysis was also performed in benign tissue around and away from the tumor as internal negative control. Additionally, 36 diagnostic biopsy specimens of patients who had documented metastasis during their follow up were assessed for CD151 immunoreactivity. A database of patient demographic factors, disease factors and relevant survival information was generated and correlated with disease-free progression and survival. Results: CD151 immunoreactivity was higher in malignant tissue than in either benign tissue around (p=0.01) or away from the tumor (p<0.01) in RP specimens. There was a strong correlation between CD151 expression in the prostatic luminal epithelium and time to biochemical recurrence (p=0.022) following RP. Importantly, there was a significant correlation between CD151 expression and metastasis (p<0.01) in these patients. In biopsies obtained at diagnosis, CD151 immunoreactivity was associated with overall metastasis (p<0.01), bone metastasis (p=0.01), and hormone resistance (p<0.01). Conclusions: Patients who were CD151 positive as assessed with mAb 1A5 had earlier biochemical failure and a significantly higher incidence of metastasis. In the RP group, these early failures likely represented a subset of patients that harbored unrecognized micrometastatic disease. The detection of CD151 adds significant prognostic value to the prediction of biochemical failure and shows considerable promise at initial biopsy to discriminate patients with higher risk of metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2260. doi:10.1158/1538-7445.AM2011-2260
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».